Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 117 articles: HTML format

Single Articles

September 2026
1. SUZUKI T, Matsuura K, Hashimoto Y, Okina M, et al
   B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study
   J Gastroenterol. 2026 Sep 4. doi: 10.1007/s00535-026-02515.
   PubMed     Abstract available
   
   
   August 2026
2. NAKAJIMA A, Okanoue T, Hiasa Y, Takahashi H, et al
   Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.
   J Gastroenterol. 2026 Aug 28. doi: 10.1007/s00535-026-02507.
   PubMed     Abstract available
   
   
   
3. ZHOU LX, Wan BY, Dong H, Shi AL, et al
   Reply to: comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".
   J Gastroenterol. 2026 Aug 10. doi: 10.1007/s00535-026-02497.
   PubMed    
   
   
   July 2026
4. YASUDA K, Iida N, Takeshita Y, Masuo Y, et al
   Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.
   J Gastroenterol. 2026 Jul 30. doi: 10.1007/s00535-026-02488.
   PubMed     Abstract available
   
   
   
5. FAN Z, Li L
   Comment on "Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer".
   J Gastroenterol. 2026 Jul 28. doi: 10.1007/s00535-026-02490.
   PubMed    
   
   
   
6. SEKO Y, Yamaguchi K
   Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan.
   J Gastroenterol. 2026;61:880-908.
   PubMed     Abstract available
   
   
   June 2026
7. YASUURA N, Suda G, Ohara M, Yokoyama D, et al
   Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.
   J Gastroenterol. 2026 Jun 26. doi: 10.1007/s00535-026-02473.
   PubMed     Abstract available
   
   
   
8. SOUSA JM, Rodriguez-Tajes S, Hernandez-Guerra M, Casado M, et al
   Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.
   J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02442.
   PubMed     Abstract available
   
   
   
9. AKUTA N, Kogiso T, Ikejima K, Otsuka M, et al
   Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
   J Gastroenterol. 2026;61:693-710.
   PubMed     Abstract available
   
   
   
10. KAWATA K, Takahashi H, Arai T, Seko Y, et al
    Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests.
    J Gastroenterol. 2026;61:783-795.
    PubMed     Abstract available
    
    
    May 2026
11. SONG C, Zhou Z, Li X
    Comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".
    J Gastroenterol. 2026 May 18. doi: 10.1007/s00535-026-02444.
    PubMed    
    
    
    
12. MIWA T, Hsu CL, Shimizu M, Bloom PP, et al
    Covert hepatic encephalopathy as a multi-organ syndrome: the gut-liver-muscle-brain axis, diagnosis, treatment, and multidisciplinary care.
    J Gastroenterol. 2026 May 8. doi: 10.1007/s00535-026-02425.
    PubMed     Abstract available
    
    
    
13. HASHIMOTO D, Ikeura T, Maekawa A, Nakajima T, et al
    Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study.
    J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02432.
    PubMed     Abstract available
    
    
    
14. OBA A, Taguchi T, Fujikawa N, Okami S, et al
    Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.
    J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02431.
    PubMed     Abstract available
    
    
    
15. YOSHIDA Y, Kumada T, Hirooka M, Ogawa S, et al
    Steatosis index: a novel multiparametric ultrasound approach for accurate liver steatosis quantification and grading.
    J Gastroenterol. 2026;61:592-602.
    PubMed     Abstract available
    
    
    
16. WU J, Miao H, Yuan W, Yao Y, et al
    Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injury.
    J Gastroenterol. 2026;61:603-624.
    PubMed     Abstract available
    
    
    April 2026
17. KANAI M, Sakai A, Date T, Aoki Y, et al
    HBV-induced miR-4461 downregulation correlates with elevated fibrinogen alpha chain expression in hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 30. doi: 10.1007/s00535-026-02433.
    PubMed     Abstract available
    
    
    
18. LIN C, Kang S, Zhang J, Yu W, et al
    The vessels encapsulating tumor clusters (VETC) pattern is a negative predictor for first-line immune checkpoint inhibitors alone in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 24. doi: 10.1007/s00535-026-02421.
    PubMed     Abstract available
    
    
    
19. IKEHARA T, Otsu H, Tobo T, Hosoda K, et al
    Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 20. doi: 10.1007/s00535-026-02380.
    PubMed     Abstract available
    
    
    
20. CHI CT, Huang YH
    Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy.
    J Gastroenterol. 2026 Apr 20. doi: 10.1007/s00535-026-02411.
    PubMed     Abstract available
    
    
    
21. SHI F, Peng Z, Lian S, Mai Q, et al
    Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02406.
    PubMed     Abstract available
    
    
    
22. KUMADA T, Toyoda H, Ogawa S, Gotoh T, et al
    Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach.
    J Gastroenterol. 2026 Apr 2. doi: 10.1007/s00535-026-02403.
    PubMed     Abstract available
    
    
    
23. REN X, Yan C, Liu X, Jia X, et al
    Bifidobacterium bifidum CIP-01 attenuates metabolic dysfunction-associated steatotic liver disease induced by high-alcohol-producing Klebsiella pneumoniae.
    J Gastroenterol. 2026;61:462-476.
    PubMed     Abstract available
    
    
    March 2026
24. ONO A, Miura R, Hayes CN, Kawaoka T, et al
    Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".
    J Gastroenterol. 2026 Mar 25. doi: 10.1007/s00535-026-02390.
    PubMed    
    
    
    
25. ZHANG F, Wang YS, Liu LX, Wang JZ, et al
    Reply to "Checking the shape of hepatocellular carcinoma: How irregular is irregular?".
    J Gastroenterol. 2026 Mar 21. doi: 10.1007/s00535-026-02394.
    PubMed    
    
    
    February 2026
26. SUN X, Zhang Y, Zhang X, Qin Q, et al
    Hepatocyte-specific yes-associated protein knockout exacerbates non-alcoholic steatohepatitis by upregulating PCSK9.
    J Gastroenterol. 2026 Feb 27. doi: 10.1007/s00535-026-02372.
    PubMed     Abstract available
    
    
    
27. LIU J, Jia T
    Letter to the editor to ''Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis''.
    J Gastroenterol. 2026 Feb 24. doi: 10.1007/s00535-026-02375.
    PubMed    
    
    
    
28. ADNAN M, Khan S, Thasleem H, Imran J, et al
    IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2026 Feb 21. doi: 10.1007/s00535-026-02360.
    PubMed    
    
    
    
29. HUO TI, Ho SY
    Checking the shape of hepatocellular carcinoma: how irregular is irregular?
    J Gastroenterol. 2026 Feb 8. doi: 10.1007/s00535-026-02359.
    PubMed    
    
    
    
30. IMAOKA K, Ohira M, Yano T, Bekki T, et al
    Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02349.
    PubMed     Abstract available
    
    
    
31. MYOJIN Y, Hikita H
    Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.
    J Gastroenterol. 2026;61:117-130.
    PubMed     Abstract available
    
    
    January 2026
32. SHEN L, Lv T, Li S, Chen S, et al
    Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jan 13. doi: 10.1007/s00535-025-02342.
    PubMed     Abstract available
    
    
    December 2025
33. REN B, Li H, Liu S, Huang Z, et al
    Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis.
    J Gastroenterol. 2025;60:1535-1553.
    PubMed     Abstract available
    
    
    
34. TSURUSAKI M, Sofue K, Murakami T, Tanigawa N, et al
    Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.
    J Gastroenterol. 2025;60:1471-1480.
    PubMed     Abstract available
    
    
    November 2025
35. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    PubMed     Abstract available
    
    
    
36. ZHOU LX, He CH, Dong H, Gao TM, et al
    Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.
    J Gastroenterol. 2025 Nov 8. doi: 10.1007/s00535-025-02317.
    PubMed     Abstract available
    
    
    
37. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    PubMed     Abstract available
    
    
    
38. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    PubMed     Abstract available
    
    
    October 2025
39. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
    Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
    J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
    PubMed     Abstract available
    
    
    
40. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
    Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
    PubMed     Abstract available
    
    
    
41. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    PubMed     Abstract available
    
    
    
42. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    PubMed     Abstract available
    
    
    
43. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    PubMed     Abstract available
    
    
    
44. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
    Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
    J Gastroenterol. 2025;60:1296-1309.
    PubMed     Abstract available
    
    
    
45. LEE J, Cha JH, Cho HS, Yang K, et al
    The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
    J Gastroenterol. 2025;60:1284-1295.
    PubMed     Abstract available
    
    
    August 2025
46. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    PubMed     Abstract available
    
    
    
47. KIDO H, Mizukoshi E, Yanagi M, Shihui L, et al
    Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease.
    J Gastroenterol. 2025;60:990-999.
    PubMed     Abstract available
    
    
    July 2025
48. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
    Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
    J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
    PubMed     Abstract available
    
    
    
49. TSUTSUMI T, Kawaguchi T, Fujii H, Kamada Y, et al
    Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
    J Gastroenterol. 2025;60:891-904.
    PubMed     Abstract available
    
    
    
50. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
    Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
    J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
    PubMed     Abstract available
    
    
    June 2025
51. OFUCHI T, Otsu H, Hosoda K, Ikehara T, et al
    VPS45 promotes the progression of hepatocellular carcinoma by recycling beta1 integrin to the cell membrane via the endocytic pathway.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02278.
    PubMed     Abstract available
    
    
    
52. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
    Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
    PubMed     Abstract available
    
    
    
53. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    PubMed     Abstract available
    
    
    May 2025
54. ONO A, Hayes CN, Miura R, Kawaoka T, et al
    Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.
    J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251.
    PubMed     Abstract available
    
    
    
55. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    PubMed     Abstract available
    
    
    
56. XIA M, Lu Y, Yin F, Cao Z, et al
    The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.
    J Gastroenterol. 2025;60:621-631.
    PubMed     Abstract available
    
    
    April 2025
57. ZHANG Y, Che N, Wang S, Meng J, et al
    Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246.
    PubMed    
    
    
    
58. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    PubMed     Abstract available
    
    
    
59. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
    Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    J Gastroenterol. 2025;60:456-468.
    PubMed     Abstract available
    
    
    March 2025
60. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
    PubMed     Abstract available
    
    
    
61. AOKI T, Kudo M, Nishida N, Ueshima K, et al
    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233.
    PubMed     Abstract available
    
    
    
62. DU T, Huang Y, Lv Y, Yuan G, et al
    Liver fibrotic burden across the spectrum of hypothyroidism.
    J Gastroenterol. 2025;60:315-327.
    PubMed     Abstract available
    
    
    
63. WANG H, Liu Z, Fan H, Guo C, et al
    Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
    J Gastroenterol. 2025;60:306-314.
    PubMed     Abstract available
    
    
    February 2025
64. NISHIMURA T, Tada T, Akita T, Kondo R, et al
    Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
    J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224.
    PubMed     Abstract available
    
    
    
65. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    PubMed     Abstract available
    
    
    
66. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
    Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
    J Gastroenterol. 2025;60:210-221.
    PubMed     Abstract available
    
    
    
67. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    PubMed     Abstract available
    
    
    January 2025
68. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    PubMed     Abstract available
    
    
    
69. ZHANG X, Li J, Yao Y, Zhou M, et al
    Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
    J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212.
    PubMed     Abstract available
    
    
    
70. KASAI Y, Ito T, Masui T, Nagai K, et al
    Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
    J Gastroenterol. 2025;60:1-9.
    PubMed     Abstract available
    
    
    December 2024
71. ZHANG F, Wang YS, Li SP, Zhao B, et al
    Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
    J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202.
    PubMed     Abstract available
    
    
    
72. MIURA R, Ono A, Nakahara H, Shirane Y, et al
    Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185.
    PubMed     Abstract available
    
    
    
73. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    PubMed     Abstract available
    
    
    
74. IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al
    Standard technique in Japan for measuring hepatic venous pressure gradient.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182.
    PubMed     Abstract available
    
    
    
75. RABIU L, Zhang P, Afolabi LO, Saliu MA, et al
    Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
    J Gastroenterol. 2024;59:1053-1078.
    PubMed     Abstract available
    
    
    November 2024
76. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    PubMed     Abstract available
    
    
    October 2024
77. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    PubMed     Abstract available
    
    
    
78. UENO M, Takeda H, Takai A, Morimura H, et al
    Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159.
    PubMed    
    
    
    
79. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    PubMed     Abstract available
    
    
    
80. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    PubMed     Abstract available
    
    
    
81. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    PubMed    
    
    
    
82. SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al
    Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
    J Gastroenterol. 2024;59:921-931.
    PubMed     Abstract available
    
    
    September 2024
83. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    PubMed    
    
    
    
84. UENO M, Takeda H, Takai A, Morimura H, et al
    CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150.
    PubMed     Abstract available
    
    
    
85. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    PubMed     Abstract available
    
    
    
86. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    PubMed     Abstract available
    
    
    August 2024
87. YU C, Tang Y, Liu M, Xu X, et al
    The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.
    J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144.
    PubMed     Abstract available
    
    
    
88. ZHANG Y, Che N, Wang S, Meng J, et al
    Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140.
    PubMed     Abstract available
    
    
    July 2024
89. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    PubMed     Abstract available
    
    
    
90. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    PubMed     Abstract available
    
    
    
91. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    PubMed     Abstract available
    
    
    June 2024
92. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    PubMed     Abstract available
    
    
    
93. WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al
    Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol. 2024;59:494-503.
    PubMed     Abstract available
    
    
    
94. HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al
    iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    J Gastroenterol. 2024;59:504-514.
    PubMed     Abstract available
    
    
    
95. MINO M, Sano A, Kakazu E, Matsubara H, et al
    Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.
    J Gastroenterol. 2024;59:483-493.
    PubMed     Abstract available
    
    
    May 2024
96. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    PubMed     Abstract available
    
    
    April 2024
97. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    PubMed     Abstract available
    
    
    
98. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    PubMed     Abstract available
    
    
    March 2024
99. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    PubMed     Abstract available
    
    
    
100. WANG J, Zhang H, Chen L, Fu K, et al
     CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
     J Gastroenterol. 2024;59:229-249.
     PubMed     Abstract available
     
     
     February 2024
101. WU C, Li J, Jia H, Zhao J, et al
     Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
     J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
     PubMed     Abstract available
     
     
     
102. NAMISAKI T, Sato S, Yoshiji H
     Role of combined aerobic and resistance exercise in liver cirrhosis.
     J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
     PubMed    
     
     
     January 2024
103. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
     Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
     J Gastroenterol. 2024;59:56-65.
     PubMed     Abstract available
     
     
     
104. HANAI T, Nishimura K, Unome S, Miwa T, et al
     A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
     J Gastroenterol. 2024;59:45-55.
     PubMed     Abstract available
     
     
     December 2023
105. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
     Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
     J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
     PubMed     Abstract available
     
     
     
106. ICHITA C, Goto T, Shimizu S
     Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
     J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
     PubMed    
     
     
     
107. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
     Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
     J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
     PubMed    
     
     
     November 2023
108. YANG Z, Shi M, Liang Y, Zhang F, et al
     Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
     J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
     PubMed     Abstract available
     
     
     
109. TADA F, Hiraoka A, Tada T, Hirooka M, et al
     Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
     J Gastroenterol. 2023;58:1134-1143.
     PubMed     Abstract available
     
     
     October 2023
110. WANG H, Li Y, Pu X, Liang X, et al
     MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
     J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
     PubMed     Abstract available
     
     
     
111. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
     Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
     J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
     PubMed     Abstract available
     
     
     
112. CRANE H, Gofton C, Sharma A, George J, et al
     MAFLD: an optimal framework for understanding liver cancer phenotypes.
     J Gastroenterol. 2023;58:947-964.
     PubMed     Abstract available
     
     
     September 2023
113. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
     Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
     J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
     PubMed     Abstract available
     
     
     
114. WEI M, Chen Y, Wang M, Li J, et al
     Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
     J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
     PubMed    
     
     
     
115. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
     Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
     J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
     PubMed     Abstract available
     
     
     
116. LIU C, Zhu S, Zhang J, Wu P, et al
     Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
     J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
     PubMed     Abstract available
     
     
     July 2023
117. WEI M, Chen Y, Wang M, Li J, et al
     Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
     J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum